drugset / Trial / NCT03547895
Management of Decompensated HCV Cirrhotic Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
-The limited treatment varieties of decompensated cirrhosis due to hepatitis C virus (HCV) remain a challenge. In patients with reduced hepatic reserve, DAAs may be associated with complications as worsening decompensation. The impact of DAAs therapy on mortality in decompensated cirrhosis was not investigated.
Timeline
- Start
- 2015-06-01
- Primary completion
- 2016-05-24
- Completion
- 2018-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daclatasvir | Small molecule | 60 mg | — |
| Comparator | Ribavirin | Small molecule | 200 mg | — |
| Comparator | Ribavirin | Small molecule | 400 mg | — |
| Comparator | Sofosbuvir | Small molecule | 400 mg | — |
| Comparator | Albumin | Protein / enzyme biologic | — | — |
| Comparator | Furosemide | Other / unclassified | — | — |
| Comparator | Phytomenadione | Unknown | 10 mg | — |
| Comparator | Silymarin | Traditional medicine (herbal / TCM) | 140 mg | — |
| Comparator | Spironolactone | Small molecule | — | — |